Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prostate cancer vaccine - Jenner Biotherapies

Drug Profile

Prostate cancer vaccine - Jenner Biotherapies

Alternative Names: JBT 1001; OncoVax-Pr

Latest Information Update: 24 Aug 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jenner Biotherapies (CEASED)
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 24 Aug 2005 No development reported - Phase-II for Prostate cancer in USA (Injection)
  • 22 Aug 2000 A interim analysis of a phase II trial has been added to the Cancer therapeutic trials section
  • 04 Mar 1999 Jenner Biotherapies has been awarded a US patent covering the use of prostate-specific antigen in prostate cancer vaccines
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top